Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Sunday's Bonus Story
Viking Therapeutics Faces Timeline Risk—But Upside Could Be HugeAuthor: Chris Markoch. Originally Published: 5/1/2026. 
Key Points
- Viking Therapeutics stock reflects the long timelines of clinical-stage biotech, with key VK2735 trial results not expected until 2027.
- The company’s dual-track GLP-1 strategy, including injectable and oral drugs, positions it to compete in a fast-growing weight-loss market.
- Strong cash reserves support operations into 2028, but dilution risk and rising competition remain key concerns for investors.
- Special Report: Elon Musk’s $1 Quadrillion AI IPO
Buy the story, sell the news. That’s a reasonable explanation for why Viking Therapeutics (NASDAQ: VKTX) fell more than 3% the day the company released its Q1 2026 earnings report. For investors unfamiliar with Viking, it’s important to note the company is not profitable and remains pre-revenue. So, judging the company by headline earnings numbers isn’t useful. As a biotechnology company, the relevant lens is its FDA timeline—where Viking sits in the regulatory process determines the risk/reward profile. The FDA pathway takes time, which creates the potential for sizable long-term upside for investors willing to accept near-term volatility. Defining the Opportunity
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itself - it's the infrastructure behind it.
One small-cap company supplies a mission-critical component to Musk's xAI Colossus site that can't be built around. While retail waits for a ticker that doesn't exist yet, early money is moving into this supplier at a fraction of its potential value. See the small-cap stock powering the SpaceX buildout today
Viking is a relatively new player in the GLP-1 space, which is currently dominated by Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO). Both incumbents are grappling with the challenge of scaling production to meet surging demand. That constraint opens a potential opportunity for smaller entrants such as Viking, and it helps explain why investors are "buying the story." Unlike many competitors, Viking is pursuing a two-track approach: both an injectable (subcutaneous) and an oral formulation of the same candidate. If successful, that strategy could differentiate the company in a crowded field. Progress Takes TimeThe injectable candidate (VK2735) is the more advanced program. Its Phase 2 (VENTURE) trial completed in 2025 and the results were published in the peer-reviewed journal Obesity in January 2026. Viking has reported full enrollment in the VANQUISH-1 (adults with obesity) and VANQUISH-2 (adults with obesity and type 2 diabetes) trials. These are 78-week studies, so investors should not expect topline results until the second half of 2027 at the earliest. The oral formulation of VK2735 is progressing as well. Viking completed an end-of-Phase 2 meeting with the FDA in December 2025 and, based on that feedback, plans to advance the oral candidate to Phase 3. That is not expected until Q4 2026, roughly six months behind the injectable program. The timing gap matters because Viking does not have the market to itself—companies like Lilly already have oral GLP-1 pills available, which could limit Viking’s addressable market even if it secures approval. Progress Takes MoneyIf VK2735 succeeds, Viking would enter the GLP-1 market with both injectable and oral options—an attractive positioning given consumer preference for pills. But advancing candidates through late-stage trials requires substantial cash. Viking ended the quarter with approximately $603 million, which management says should fund operations into 2028. That runway should be sufficient to advance the injectable program through its current clinical phases. To help mitigate execution risk, Viking has also signed a comprehensive agreement with CordenPharma. However, the company burned more cash than expected in the quarter, which likely contributed to the selloff. If Viking runs short of cash, it would probably raise funds via a share offering, which would be dilutive to existing shareholders. The Wildcard That Could Redefine the OpportunityBeyond VK2735, Viking has filed an investigational new drug (IND) application for its VK3019 candidate, a novel amylin agonist that targets amylin and calcitonin receptors involved in appetite and metabolic control. Viking believes dual activation of these receptors could be an attractive option for patients who are not candidates for GLP-1 therapies. The company plans to initiate a Phase 1 trial for VK3019 in Q2 2026. How to Make Time Your Friend With VKTXShort interest in VKTX is around 21% and institutional ownership is roughly 76%, which can create headwinds for retail investors. That dynamic helps explain why VKTX is down more than 14% in 2026 despite encouraging clinical progress. Still, Viking is covered by 13 analysts who collectively assign a consensus price target of $95.50, implying potential upside of more than 200% from current levels. Given the short-term volatility and cash burn risk, a measured approach may make sense. Consider dollar-cost averaging or initiating a small starter position and adding tranches as the company hits clinical and regulatory milestones to help manage risk while keeping exposure to the potential upside. |
Post a Comment
Post a Comment